{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:46:46Z","timestamp":1793810806182,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jiac.2025.102760","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:22:51Z","timestamp":1750216971000},"page":"102760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiviral treatment for influenza in Japan"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9628-9125","authenticated-orcid":false,"given":"Tadashi","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102760_bib1","volume":"vol. 40","year":"2019"},{"key":"10.1016\/j.jiac.2025.102760_bib2","first-page":"20","volume":"vol. 9","year":"2024"},{"key":"10.1016\/j.jiac.2025.102760_bib3","series-title":"Australian respiratory surveillance report","year":"2024"},{"key":"10.1016\/j.jiac.2025.102760_bib4","series-title":"Weekly report of influenza, the 2024-2025 season","first-page":"9","volume":"vol. 1","year":"2025"},{"key":"10.1016\/j.jiac.2025.102760_bib5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on Diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib6","first-page":"11","article-title":"The treatment guidelines for adult patients with novel influenza","year":"2017","journal-title":"Ver.2"},{"key":"10.1016\/j.jiac.2025.102760_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jiac.2022.02.001","article-title":"Clinical manifestations of hospitalized influenza patients without risk factors: a prospective multicenter cohort study in Japan via internet surveillance","volume":"23","author":"Ishida","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4779","article-title":"Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China","volume":"341","author":"Yu","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2025.102760_bib9","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/jac\/dkq511","article-title":"Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A","volume":"66","author":"Rodriguez","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiac.2025.102760_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2025.102760_bib12","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2025.102760_bib13","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/cix127","article-title":"Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1) pdm09 at high risk of hospitalization: an individual participant data meta-analysis","volume":"64","author":"Venkatesan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib14","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1093\/jac\/dkx271","article-title":"Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and\/or meta-analyses","volume":"72","author":"Doll","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib15","article-title":"Antiviral medications for treatment of nonsevere influenza: a systematic review and network meta-analysis","volume":"13","author":"Gao","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jiac.2025.102760_bib16","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMra1000449","article-title":"Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102760_bib17","unstructured":"Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinician. 2023.12.8 influenza antiviral medications: summary for clinicians | influenza (Flu) | CDC."},{"key":"10.1016\/j.jiac.2025.102760_bib18","first-page":"250","volume":"vol. 31","year":"2010"},{"key":"10.1016\/j.jiac.2025.102760_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/jinf.1999.0602","article-title":"Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study","volume":"40","author":"M\u00e4kel\u00e4","year":"2000","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2025.102760_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200005000-00005","article-title":"Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial","volume":"19","author":"Hedrick","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiac.2025.102760_bib22","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(13)61125-3","article-title":"Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance","volume":"381","author":"Hu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2025.102760_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/509925","article-title":"Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children","volume":"44","author":"Sugaya","year":"2007","journal-title":"Clin Infect Di"},{"key":"10.1016\/j.jiac.2025.102760_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102760_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/589748","article-title":"Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children","volume":"47","author":"Sugaya","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib27","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib28","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib29","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/cid\/ciu632","article-title":"Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients","volume":"59","author":"de Jong","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.00132-11","article-title":"Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection","volume":"56","author":"Sugaya","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib31","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, non-inferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib32","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate(CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jiac.2018.04.013","article-title":"Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016\/17 Japanese influenza season; comparison with the 2011\/12 to 2015\/16 seasons","volume":"24","author":"Ikematsu","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib34","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jiv245","article-title":"Emergence of multidrug-resistant Influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with Oseltamivir and Zanamivir","volume":"212","author":"Tamura","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2025.102760_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jiac.2025.102760_bib36","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib37","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jiac.2020.04.014","article-title":"Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: a post marketing surveillance of more than 3000 patients","volume":"26","author":"Nakazawa","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib39","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jmii.2021.04.002","article-title":"Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Kuo","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2025.102760_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jiac.2023.10.017","article-title":"Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: a systematic review and meta-analysis","volume":"30","author":"Shiraishi","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102760_bib41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children. A randomized, double blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiac.2025.102760_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/infdis\/jiaa061","article-title":"Detection of variants with reduced baloxavir marboxil susceptibility after treatment of children with influenza A during the 2018-2019 influenza season","volume":"222","author":"Sato","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102760_bib45","doi-asserted-by":"crossref","unstructured":"Chow EJ, Beigi RH, Riley LE, et al. Clinical effectiveness and safety of antivirals for influenza in pregnancy. Open Forum Infect Dis Mar 20; 8: ofab138.doi: 10.1093\/ofid\/ofab138. eCollection 2021 Jun.","DOI":"10.1093\/ofid\/ofab138"},{"key":"10.1016\/j.jiac.2025.102760_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102760_bib47","series-title":"The guidelines for infectious diseases","year":"2023"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:48:57Z","timestamp":1762368537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1341321X25001576"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102760","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral treatment for influenza in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102760"}}